cyrilzakka/clinical-trials huggingface dataset:
Evolution of Symptoms After Sacrospinofixation With Posterior Isthmic Band

Prolapse is a condition that can cause disabling pelvic, urinary or sexual function disorders and impaired quality of life.

Regarding the prolapse of the middle floor, the vaginal sacrospinofixation according to Richter is the reference technique for the suspension of the vaginal fundus. But the technique of sacrospinofixation vaginally is not without several difficulties in the short term but also in the medium and long term.

Recently, anchoring devices have been developed to limit the dissection of the sacrospinous ligament and the operative exposure by the sometimes traumatic valves.

The investigating team uses a technical variant in the form of an isthmic posterior strip of light weight and whose arms are sutured to the sacrospinous ligaments. The advantages of this isthmic strip are based on its small size, its very low basis weight and its wide mesh (improvement of tolerance) via a mini-invasive vaginal approach (thus allowing ambulatory care).

Patient functional discomfort is the main problem related to the presence of a prolapse, therefore, the researchers wish to evaluate patient feelings following the use of this isthmic band. The researchers' hypothesis is that the sacrospinofixation technique with posterior isthmic band Bilateral Sacrospinous Colposuspension (BSC) Mesh (Agency for Medical Innovations (AMI) laboratory) improves symptoms experienced by patients with mid-level prolapse.


Eligibility Criteria:
Inclusion Criteria:

* women over 18
* apical prolapse requiring surgical correction of grade II or greater in the Pelvic Organ Prolapse Quantification (POP-Q) classification
* patients who wish an intervention because of the discomfort caused by prolapse
* sacrospinofixation procedure with posterior isthmic band Bilateral Sacrospinous Colposuspension (BSC) Mesh provided
* person having expressed his non-opposition

Exclusion Criteria:

* apical prolapse of stage \< II in the Pelvic Organ Prolapse Quantification (POP-Q) classification, and prolapse without functional discomfort
* disorders leading to an unacceptable risk of postoperative complications sought during the interrogation of the patient (disorders of blood coagulation, disorders of the immune system, progressive diseases ....)
* reduced mobility of the lower limbs (not allowing positioning for surgery)
* pregnancy or any plans for pregnancy during the study period
* evolutionary or latent infection
* known hypersensitivity to polypropylene
* inability to understand the information given
* person deprived of liberty, under guardianship.
Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)

To determine the revascularization rate of the CE-marked Trevo device in large vessel occlusions in ischemic stroke patients.

* Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro interventional procedure.

* Clinical outcomes at 90 days
* Mortality at 90 days
* Device-related serious adverse events (DRSAEs)
* Symptomatic ICH rate within 24 (-6/+12) hours post-procedure

Eligibility Criteria:
Inclusion Criteria:

* Age 18-79 (has had 18th birthday, but not yet had 80th birthday)
* NIHSS 8 - 30
* Anticipated life expectancy of at least 6 months
* No significant pre-stroke disability (mRS less than or equal to 1)
* Written informed consent to participate given by patient or legal representative
* Angiographic confirmation of a persistent large vessel occlusion, in the internal carotid, middle cerebral M1 and/or M2 segments, basilar or vertebral arteries
* Treatable within 8 hours of symptom onset, defined as the first pass being made with the Trevo device.

Exclusion Criteria:

* Baseline glucose of \< 50 mg/dL (2.78 mmol) or \> 400 mg / dL (22.20 mmol)
* Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR \> 3.0
* Treated with Heparin within 48 hours with a PTT greater than 2 times the lab normal
* Baseline platelet count \< 30,000
* History of severe allergy (more than rash) to contrast medium
* Severe, sustained hypertension (SBP \> 185 mm Hg or DBP \> 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained at the acceptable level using medication (i.e. Nipride), the patient can be enrolled
* Woman of child bearing potential who is known to be pregnant
* Patient participating in another clinical study or protocol
* For anterior circulation strokes: strokes involving greater than 1/3 of the MCA territory, as determined by hypodensity on the baseline non- contrast CT, or low CBV on CT Perfusion imaging, or restricted diffusion on DWI images
* For posterior circulation strokes within the midbrain and/or pons, extensive hypodensity on the baseline CT, or low CBV on CT Perfusion imaging, or extensive restricted diffusion on DWI images
* Baseline CT/MR evidence of significant mass effect with midline shift
* Baseline CT/MR evidence of hemorrhage
* Baseline CT/MR evidence of intracranial tumor (except small meningioma)
* Angiographic evidence of vasculitis or arterial dissection
* High grade stenosis that cannot be treated safely or which prevents access to the thrombus with the Trevo device
* Angiographic evidence of excessive arterial tortuosity that precludes the Trevo device from reaching the thrombus
Early FDG PET in Melanoma

Adult patients with histologically proven melanoma who will be treated with pembrolizumab will undergo FDG PET/CT scan as an early evaluation of response to therapy. Changes in FDG uptake will be correlated with lab and pathology results.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, at least 18 years of age
* History of histologically confirmed melanoma as assessed per medical record review.
* Eligible for the trial UPCC #01615, "A Phase Ib Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects with Resectable Advanced Melanoma."
* Participants must be informed of the investigational nature of this study and provide written informed consent in accordance with institutional and federal guidelines prior to study-specific procedures.

Exclusion Criteria:

* Females who are pregnant or breast-feeding at the time of screening will not be eligible for this study. Female participants of child-bearing potential will have a urine or serum pregnancy test at the time of the screening visit.
* Inability to tolerate imaging procedures in the opinion of the investigator or treating physician.
* Serious or unstable medical or psychological conditions that, in the opinion of the investigator would compromise the subject's safety or successful participation in the study.
* Ineligible for the trial UPCC #01615, "A Phase Ib Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects with Resectable Advanced Melanoma."
* Only individuals (aged 18 or over) who can understand and give informed consent will be eligible to participate in this study. Individuals who are considered to be mentally disabled will not be recruited for this study. All subjects must be able to give informed consent. We will not be using specific methods to assess decisional capacity. Economically disadvantaged persons will not be vulnerable to undue influence, as this study offers no compensation. All individuals will be told that their choice regarding study participation will in no way change their access to clinical care. This should negate any undue influence or coercion. Children, fetuses, neonates, or prisoners are not included in this research study.
Role of Skin Cleansing and Prophylactic Antibiotic in Preventing Infectious Morbidity After Cesarean Section Delivery

This study aims to determine the effectiveness of skin cleansing and prophylactic antibiotics given to women undergoing a cesarean section for reducing the incidence of postpartum infectious morbidity and to assess potential maternal adverse effects and any impact on the infant.


Eligibility Criteria:
Inclusion Criteria:

1. Women undergoing cesarean delivery, both elective and non-elective.
2. Rupture of membranes and labor contractions will be allowed.

Exclusion Criteria:

1. Unknown outcome from the patient.
2. Refusing to participate in the study from the admission conse
3. Allergy to antibiotics.
4. Any visible infection.
Effect of Folic Acid and/or Pentoxifylline on Patients With Chronic Kidney Disease

The aim of this study is to evaluate the effect of administration of folic acid and /or pentoxifylline on patients with chronic kidney disease (CKD).

Chronic kidney disease (CKD) is a worldwide public health problem, with adverse outcomes of kidney failure, cardiovascular disease (CVD), and premature death. Chronic kidney disease (CKD) affects between 8% and 16% of the population worldwide.Defined by a glomerular filtration rate (GFR) of less than 60 mL/min/1.73 m2, albuminuria of at least 30 mg per 24 hours, or markers of kidney damage (eg, hematuria or structural abnormalities such as polycystic or dysplastic kidneys) persisting for more than 3 months.That nutrient loss because of diet restriction and chronic inflammation contributed by CKD itself may stimulate progression in advanced chronic kidney disease. Folic acid was then selected as a nutrient intervention. In the mean time, pentoxifylline was well studied in this field for its anti-inflammatory effects.Pentoxifylline (PTF) appears to improve circulation through its ability to alter erythrocyte deformability and enhances capillary microcirculation. This hemorheological property and the potential capacity in decreasing intraglomerular pressure has led to recent interest in PTF as a therapeutic agent in patients with kidney disease. In addition to these properties, PTF has an effect on inflammation, oxidative stress and endothelial function.

Eligibility Criteria:
Inclusion Criteria:

1. Patients who have chronic kidney disease(CKD) stages 3-5
2. Aged between18 - 60 years old.
3. Both sexes.
4. Stable clinical condition defined as no hospitalizations or cardiovascular events within the 3 months before screening
5. Stable renal function (baseline serum creatinine had to have not increased by 50% in the 3 months before screening)
6. No changes in concomitant medication during the study.
7. Patients who accept to participate in the study.

Exclusion Criteria:

1. Pregnant women
2. Current use of PTF
3. Contraindication to use of PTF drug: history of PTF or theophylline allergy, history of severe retinal hemorrhage or recent cerebral hemorrhage
4. Those with active infections or inflammatory diseases or HIV infection
5. Those with chronic liver disease .
6. Patients who had received immunosuppressive therapy
7. Non-compliant patients
Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Reducing Postoperative Pocket Pain

Bupivacaine is the most widely used local anesthetic agent across majority of the Cardiac Implantable Electronic device (CIED) implant procedures in the United States. It is hypothesized that the combination of Bupivacaine-Ketorolac-Ketamine (BKK) is more effective in alleviating perioperative and postoperative pain as compared to the use of bupivacaine alone.

A few studies have been done to look for the effectiveness of BKK in abdominal surgical procedures. However, no study has been done to evaluate its efficacy and effectiveness in patients undergoing CIED insertion.

Bupivacaine is a widely used local anesthetic and is often administered by spinal injection prior to major surgical procedures. Ketorolac is a potent NSAID which is used for the short-term relief of moderate to severe pain. It's used for long term duration is generally limited due to its potential to cause GI ulcers/perforation and renal failure. A single dose of perioperative Ketorolac has been found to be effective in reducing opioid consumption. Ketamine is NMDA receptor antagonist and is used for its anesthetic, analgesic, and psychotomimetic effects. It is primarily used for induction and maintenance of anesthesia and induces a trance like state providing pain relief, sedation, and amnesia.

Although an effective local anesthetic agent, bupivacaine has weak analgesic effect and is used in combination with several analgesic agents for effective perioperative and postoperative analgesia. A common drug used in this analgesic regimen usually includes opioids such as morphine, oxycodone, and fentanyl. Over the last few decades the United States has witnessed an opioid epidemic and post-surgical opioid prescription is one of the major contributors of this epidemic. An opioid free combination of Bupivacaine-Ketorolac-Ketamine (BKK) is thought to be effective in alleviating perioperative and postoperative pain.

Eligibility Criteria:
Inclusion Criteria:

* Both male and female patients
* Patients older than 18 years of age
* Patients undergoing new CIED (ICD, pacemaker, CRT-D or CRT-P)
* Patients willing to participate in the study

Exclusion Criteria:

* Patients with prior history of allergic reaction to any component of the drug; bupivacaine, ketorolac, or ketamine
* Pregnant or breastfeeding patients
* Prisoners
* Patients younger than 18 years of age
* Patients not willing to participate in the study
* Patients deemed not suitable or unstable for the study as per physician's discretion
Effects of Electronic Cigarettes in Cigarette Smokers With Mild to Moderate COPD

This study evaluates the effects of electronic cigarette use on cigarette smoking and markers of tobacco use, as well as respiratory symptoms and function in smokers with mild to moderate chronic obstructive pulmonary disease (COPD). All participants will receive a 12 week supply of electronic cigarettes to use instead of their regular conventional cigarettes.

Electronic cigarettes are devices that heat a solution containing nicotine to form an aerosol that is then inhaled by the user. Electronic cigarettes are used by many smokers, including smokers with chronic health conditions such as COPD. Given that e-cigarettes are still relatively new, their effects on health are not well defined.

It is important to understand how electronic cigarettes affects symptoms and lung function in smokers with COPD to determine the short-term safety of these products. To do this, an initial step involves observing the extent to which smokers substitute their conventional cigarette use with electronic cigarette use and change their exposure to tobacco use biomarkers.

Eligibility Criteria:
Inclusion Criteria:

* At least 10 pack year smoking history
* Daily use of at least 5 cigarettes
* No plan to quit cigarettes in the next 30 days
* Willing to use e-cigarettes
* Diagnosis of COPD (FEV1/forced vital capacity \[FVC\] \<0.70) with mild (FEV1 \>80% predicted) or moderate (FEV1 \<80% but \>50% predicted) airflow limitation (post-bronchodilator); confirmed by spirometry
* English-speaking

Exclusion Criteria:

* Past 30-day use of nicotine-containing products (cigars, cigarillos, hookah, electronic cigarettes, smokeless tobacco, nicotine replacement therapy)
* Past 30 day use of inhaled drugs (marijuana, crack)
* Pregnant or breastfeeding
* Planning to become pregnant within the next 3 months or unable to agree to use appropriate contraception during study
* Pulmonary disease other than COPD or asthma
* Ever requiring mechanical ventilation
* 2 or more hospitalizations for COPD in the past 12 months
* Cardiac hospitalization in the past 6 months
* Active chest pain or palpitations
* Uncontrolled hypertension (blood pressure \>160/100)
* Oxygen therapy
* Inability or contraindication to perform spirometry (e.g. recent eye, thoracic, or abdominal surgery)
* Known allergy to propylene glycol or vegetable glycerin
* Unable to consent or complete assessments
Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women

We will be examining the effects of suppressive valacyclovir therapy on the stability of vaginal flora in women who are seropositive for HSV-2. We have preliminary data that suggests the presence of HSV-2 increases the risk for Group B Streptococcus colonization as well as many other deleterious organisms (e.g. Streptococcus pseudoporcinus), in addition to increasing the risk for acquisition of BV-associated vaginal flora. We will be examining the effects of suppressive therapy on the vaginal flora of any HSV-2 seropositive woman.


Eligibility Criteria:
Screening Inclusion Criteria:

* Women 18-40 years of age at the time of screening
* Willing to be screened for HSV-2 using a rapid, FDA approved test
* Using an effective method of birth control (examples of effective methods of birth control are: women practicing abstinence x 90 days, hormonal birth control, consistent condom use, bilateral tubal ligation, partner with a vasectomy)

Screening Exclusion Criteria:

* Pregnant or nursing mother
* Use of any antimicrobial agents (vaginal or systemic) for the treatment of any condition within 7 days
* Presence of any intrauterine device
* Allergy or hypersensitivity to valcyclovir or nucleoside analogues

Enrollment Inclusion Criteria:

* Women 18-40 Years of age at the time of screening
* HSV-2 seropositive as determined by rapid HSV-2 testing
* Using an effective method of birth control (examples of effective methods of birth control are: women practicing abstinence x 90 days, hormonal birth control, consistent condom use, bilateral tubal ligation, partner with a vasectomy)
* Willing to avoid use of any intravaginal products during study period
* Capable of providing written informed consent
* Capable of cooperating to the extent and degree required by this protocol

Enrollment Exclusion Criteria:

* Pregnancy (all women will have a urine pregnancy test prior to randomization and treatment)
* nursing mother
* Menopausal women
* Use of any antimicrobial agents (vaginal or systemic) for the treatment of any condition within 7 days of study enrollment
* Known immunocompromised state
* Significant Medical disorder that precludes accurate evaluation of participants condition
* Presence of any intrauterine device
* History of significant hepatic or renal impairment
* Sensitivity/allergy to valacyclovir or nucleoside analogues
* history of acyclovir or valacyclovir resistant HSV infection
* Participation in a study using an investigational product in the past 30 days
Cervical Range of Motion in Neck Pain Patients: A Mixed Methods Study

This study there are any associations between objective and subjective outcome measures, measuring the cervical range of motion and if the restriction matter to the patient.

Objective and subjective outcome measures are frequently used assessments in clinical practice.

The investigators will use different subjective and objective outcome measures to evaluate any possible associations, as well as to investigate if restrictions of movement matters to patients.

Additionally to the assessments tools the investigators will use interviews to extend the scope.

Eligibility Criteria:
Inclusion Criteria:

* Patients with any duration of neck pain
* Men and women older than 18 years
* Signed informed consent

Exclusion Criteria:

* Disc herniation of the cervical spine
* Spinal canal stenosis
* Acute accidents
* Surgery of the cervical spine
* Pacemaker and / or defibrillator
Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease

Aspirin-Exacerbated Respiratory Disease, or AERD, consists of aspirin sensitivity, asthma and nasal polyps. It is currently managed by chronic steroid use, multiple endoscopic sinus surgeries and/or aspirin desensitization. However, these treatments have potential adverse effects.

A theory has been postulated that decreasing the level of dietary salicylates may help in long-term control of disease. A current trial is in the works to evaluate the clinical outcomes of decreased salicylate, but measurements of biochemical markers of disease has not yet been done. The hypothesis is that decreased dietary salicylates will result in a decrease in urinary salicylates and inflammatory markers of disease, cys-leukotrienes, which are typically elevated in this disease.


Eligibility Criteria:
Inclusion Criteria:

* adult patients
* Aspirin-exacerbated respiratory disease

Exclusion Criteria:

* recent use of Prednisone or other systemic steroids (greater than 3 doses in past 3 months)
* Endoscopic sinus surgery or polypectomy within the past 6 months
* Other significant systemic disease, including renal failure, or immunocompromised state.
PAncreatic Adenocarcinoma in Hospital

Few data are currently available in the literature on pancreatic adenocarcinoma in France. About 8,000 new cases each year in France. The 5-year survival for all stages combined is \<5%. This is the only digestive cancer in which mortality / incidence ratio is 98%.

Epidemiological characteristics at diagnosis, the impact on the survival of recent advances related to surgery, adjuvant chemotherapy and new standard forms of adjuvant chemotherapy (FOLFIRINOX) are mispriced in real life.

The development of new drugs and the development of Phase II and III require a better understanding of the state of this disease in the country.

The main objective is to describe the characteristics of the pancreatic adenocarcinoma at diagnosis in France and make an inventory of diagnostic practices and support.


Eligibility Criteria:
Inclusion Criteria:

* Living in France
* Pancreatic adenocarcinoma histologically or cytologically proven
* primary diagnosis
* Agreed to participate

Exclusion Criteria:

* Suspected pancreatic adenocarcinoma histologically or cytologically unproven
* Refused to participate
Neural Network to Calculate Morphology of the Cleft Palate to Reduce Cleft Lip and Palate Treatment Burden.

This study is to develop a neural network to compute palatal three dimensional (3D) geometry by using routinely taken intraoral/palatal photographs and palatal casts of infants with cleft lip and palate deformity for reducing cleft lip and palate treatment burden. Data of palatal casts and palatal images of cleft patients routinely treated at the University Hospital Basel will be analyzed.The collection of large data helps in developing a neural network that will allow the computation of the 3D geometry from single photographs.


Eligibility Criteria:
Inclusion Criteria:

* Patients with cleft lip and palate malformation with available routinely performed plaster cast model from palatal impressions, intraoral scans from the palate and corresponding images of the cleft palate (1970 till 2025)

Exclusion Criteria:

* Existence of a documented rejection